| abstract |
The compounds are useful in the treatment and prophylaxis of epilepsy, migraine and other diseases. They have the formula wherein R 1 is hydrogen, C 1-6 alkyl (optionally substituted hydroxy or C 1-4 alkoxy), phenyl-C 1-4 alkyl-, C 1-6 alkenyl or C 1-6 alkynyl; R2 represents hydrogen or up to three substituents selected from halogen, NO2, CN, N3, CF3O-, CF3S-, CF3SO2-, CF3CO-, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl-, C1-6 alkylO-, C1-6 alkylCO-, C3-6 cycloalkylO-, C3-6 cycloalkylC0-, C3-6 cycloalkyl-C1-4 alkylO- , C3-6 cycloalkyl-C1-4 alkylC0-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4 alkyl-, C1-6 alkylS-, C1-6 alkylSO2-, (C1-4 alkyl) 2NSO2-, C1-4 alkyl) NHSO2-, (C1-4alkyl) 2NCO-, (C1-4alkyl) NHCO- or CONH2; or R 2 is -NR 5 R 6 wherein R 5 is hydrogen or C 1-4 alkyl and R 6 is hydrogen, C 1-4 alkyl, formyl, -CO 2 C 1-4 alkyl or -COC 1 -4 alkyl or two groups R 2 form together a carbocyclic ring which is saturated or unsaturated, optionally interrupted with O or NH2; R3 and R4 groups independently of one another are hydrogen or C1-6 alkyl and / or both R3 and / or both R4 together form a C3-6 spiroalkyl group, provided that at least one of the groups R3 or R4 is not hydrogen and X is selected from hydrogen, halogen, cyano, alkyl and alkoxy. The invention also relates to pharmaceutically acceptable salts and solvates of said compounds. |